BMS spends $2.4b on Medarex.
- Published in:
- TCE: The Chemical Engineer, 2009, n. 819, p. 5
- Publication type:
- Article
Works matching DE "MEDAREX Inc."
Results: 10
1
2
Does the patent office really believe delay occurs before it actually occurs? The effect of Wyeth et al v. Dudas on patent term adjustments.
- Published in:
- Journal of Generic Medicines, 2009, v. 6, n. 3, p. 272, doi. 10.1057/jgm.2009.6
- By:
- Publication type:
- Article
3
Deal watch: BMS bets on biologic immunotherapies.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 9, p. 688, doi. 10.1038/nrd2985
- Publication type:
- Article
4
Deal watch: Monoclonal antibodies targeting Clostridium difficile licensed to Merck.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 6, p. 442, doi. 10.1038/nrd2911
- Publication type:
- Article
5
Clinical Trials News.
- Published in:
- Applied Clinical Trials, 2004, v. 13, n. 8, p. 15
- Publication type:
- Article
6
Business digest.
- Published in:
- Chemistry & Industry, 2009, n. 17, p. 13
- By:
- Publication type:
- Article
7
Light shed on battle against HIV.
- Published in:
- Nature, 2006, v. 442, n. 7105, p. 852, doi. 10.1038/442852a
- By:
- Publication type:
- Article
8
Bristol-Myers Squibb swallows last of antibody pioneers.
- Published in:
- Nature Biotechnology, 2009, v. 27, n. 9, p. 781, doi. 10.1038/nbt0909-781
- By:
- Publication type:
- Article
9
Research collaborations.
- Published in:
- Nature Biotechnology, 2000, v. 18, n. 3, p. 247, doi. 10.1038/73622
- Publication type:
- Article
10
Ipilimumab.
- Published in:
- Drugs in R&D, 2010, v. 10, n. 2, p. 97, doi. 10.2165/11584510-000000000-00000
- Publication type:
- Article